Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 trial of HLX15-SC in the Chinese Mainland, according to a Tuesday Hong Kong bourse filing.
The drug is being tested for first-line treatment for newly diagnosed multiple myeloma, the filing said.